Univariable and MVAs of factors associated with OS
| Factor . | Level . | n . | Univariable analysis HR (95% CI) . | P value . | MVA HR (95% CI) . | P value . |
|---|---|---|---|---|---|---|
| MIPI score at diagnosis | High risk | 28 | 2.73 (1.26-5.88) | .011 | ||
| Low/intermediate risk | 29 | — | — | |||
| TP53 alterations at diagnosis∗ | Yes | 18 | 1.42 (0.63-3.14) | .398 | ||
| No | 22 | |||||
| MIPI score before venetoclax | High risk | 34 | 2.12 (1.03-4.36) | .041 | 2.36 (1.17-5.03) | .022 |
| Low/intermediate risk | 29 | — | — | |||
| Complex karyotype before venetoclax∗ | Yes | 9 | 2.04 (0.49-8.50) | .329 | ||
| No | 15 | — | ||||
| TP53 alterations before venetoclax∗ | Yes | 9 | 2.63 (0.85-8.12) | .097 | ||
| No | 19 | — | ||||
| Blastoid/pleomorphic before venetoclax | Yes | 27 | 1.77 (0.86-3.64) | .123 | ||
| No | 33 | — | ||||
| Number of lines of treatment before venetoclax | >3 | 23 | 1.19 (0.62-2.29) | .592 | ||
| ≤3 | 53 | — | ||||
| POD24 | Yes | 35 | 2.30 (1.22-4.45) | .012 | 3.81 (1.73-8.85) | .001 |
| No | 38 | — | ||||
| Best response to last therapy before venetoclax | CR, PR | 33 | 0.58 (0.29-1.16) | .125 | ||
| SD, PD | 37 | — | ||||
| Best response to BTKi | CR, PR | 43 | 0.80 (0.39-1.63) | .534 | ||
| SD, PD | 22 | — | ||||
| Duration of treatment with BTKi, mo | >6 | 35 | 0.81 (0.42-1.57) | .533 | ||
| ≤6 | 31 | — | ||||
| Reason for stopping BTKi | PD | 55 | 1.30 (0.50-3.40) | .590 | ||
| Toxicity | 12 | — | ||||
| Duration of treatment with last therapy before venetoclax, mo | >4 | 35 | 0.48 (0.25-0.92) | .026 | ||
| ≤4 | 39 | — | ||||
| Venetoclax highest dose received, mg | ≥400 | 55 | 0.97 (0.44-2.12) | .933 | ||
| <400 | 17 | — | ||||
| Venetoclax combined with other agent(s) | Yes | 31 | 0.58 (0.30-1.12) | .102 | 0.32 (0.14-0.70) | .007 |
| No | 45 | — |
| Factor . | Level . | n . | Univariable analysis HR (95% CI) . | P value . | MVA HR (95% CI) . | P value . |
|---|---|---|---|---|---|---|
| MIPI score at diagnosis | High risk | 28 | 2.73 (1.26-5.88) | .011 | ||
| Low/intermediate risk | 29 | — | — | |||
| TP53 alterations at diagnosis∗ | Yes | 18 | 1.42 (0.63-3.14) | .398 | ||
| No | 22 | |||||
| MIPI score before venetoclax | High risk | 34 | 2.12 (1.03-4.36) | .041 | 2.36 (1.17-5.03) | .022 |
| Low/intermediate risk | 29 | — | — | |||
| Complex karyotype before venetoclax∗ | Yes | 9 | 2.04 (0.49-8.50) | .329 | ||
| No | 15 | — | ||||
| TP53 alterations before venetoclax∗ | Yes | 9 | 2.63 (0.85-8.12) | .097 | ||
| No | 19 | — | ||||
| Blastoid/pleomorphic before venetoclax | Yes | 27 | 1.77 (0.86-3.64) | .123 | ||
| No | 33 | — | ||||
| Number of lines of treatment before venetoclax | >3 | 23 | 1.19 (0.62-2.29) | .592 | ||
| ≤3 | 53 | — | ||||
| POD24 | Yes | 35 | 2.30 (1.22-4.45) | .012 | 3.81 (1.73-8.85) | .001 |
| No | 38 | — | ||||
| Best response to last therapy before venetoclax | CR, PR | 33 | 0.58 (0.29-1.16) | .125 | ||
| SD, PD | 37 | — | ||||
| Best response to BTKi | CR, PR | 43 | 0.80 (0.39-1.63) | .534 | ||
| SD, PD | 22 | — | ||||
| Duration of treatment with BTKi, mo | >6 | 35 | 0.81 (0.42-1.57) | .533 | ||
| ≤6 | 31 | — | ||||
| Reason for stopping BTKi | PD | 55 | 1.30 (0.50-3.40) | .590 | ||
| Toxicity | 12 | — | ||||
| Duration of treatment with last therapy before venetoclax, mo | >4 | 35 | 0.48 (0.25-0.92) | .026 | ||
| ≤4 | 39 | — | ||||
| Venetoclax highest dose received, mg | ≥400 | 55 | 0.97 (0.44-2.12) | .933 | ||
| <400 | 17 | — | ||||
| Venetoclax combined with other agent(s) | Yes | 31 | 0.58 (0.30-1.12) | .102 | 0.32 (0.14-0.70) | .007 |
| No | 45 | — |
Variables with <50% data capture were excluded from the MVA.